SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing a massive sell-off as a weak revenue outlook and significant declines in the China market overshadow an earnings beat, fueling intense debate over whether this decade-long low represents a generational buying opportunity or a deeper structural decline. The community is sharply divided, with many traders betting on a sharp V-shaped recovery and a "juicy" dividend, while skeptics argue that the brand's long-term growth is dead and are cautioning against catching a falling knife.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 is experiencing heightened volatility as market participants weigh conflicting reports regarding geopolitical tensions in the Middle East and anticipated commentary from political leadership. Investors are actively debating whether recent gains represent a durable recovery or a bull trap, with many closely monitoring crude oil fluctuations and potential impacts on global trade as they hedge against significant uncertainty ahead of scheduled policy speeches.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending amid intense community debate over its aggressive Bitcoin-linked treasury strategy, with investors highlighting significant price volatility and concerns regarding share dilution. The conversation is currently split between those betting on long-term institutional adoption and short sellers pointing to structural leverage risks and downward price action.

Invesco QQQ Trust Series 1 - Units of beneficial interest

Invesco QQQ Trust is experiencing intense volatility and aggressive price action as traders weigh conflicting reports regarding potential ceasefire negotiations in the Iran conflict. The community is actively debating whether the current rally is a sustainable recovery or an exit liquidity trap fueled by market manipulation ahead of a highly anticipated national address by the President.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is facing significant selling pressure as investors grapple with shifting consumer sentiment and broader market volatility, with community discussions split between long-term growth optimism and concerns regarding current valuation levels. The stock is currently under a microscope as market participants debate whether these lows present a buying opportunity or a warning sign of further downward consolidation.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is experiencing intense volatility and social media attention as traders monitor its low-float structure and history of sharp, squeeze-driven price moves. The community is actively debating whether current price action signals a repeat of past parabolic runs, with many focusing on the high cost to borrow, limited share availability, and the potential for a swift short squeeze.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as investors react to a series of analyst downgrades, a recent activist stake from Jana Partners, and a disconnect between the company's strong cash flow and its depressed valuation. While some retail investors are calling it a value trap due to stagnant performance, others are actively buying the dip, citing its dominant market position and low forward P/E as evidence of a significant buying opportunity.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is trending due to significant volatility following a quarterly earnings report that featured a revenue beat but a notable miss on earnings expectations, coupled with cautious guidance linked to ongoing tariff pressures and housing market headwinds. Investors are actively debating the stock's future, weighing concerns over debt and luxury spending against potential upside from long-term global expansion and anticipation of favorable legal outcomes regarding trade tariffs.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as the community closely monitors the company's progress on scaling its proprietary hydrometallurgical facility in Bolivia and its upcoming implementation in Idaho. Investors are actively discussing the potential impact of this technology on processing critical minerals, alongside speculation regarding anticipated Department of Defense shipments and the broader strategic necessity of domestic supply chains for antimony and tungsten.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is currently facing intense selling pressure driven by a mix of weak quarterly earnings, concerns regarding equity dilution, and a class-action lawsuit alleging misleading disclosures about project partnerships. Despite this negative sentiment and short-term volatility, the community remains divided, with long-term investors pointing to the growing demand for nuclear energy in AI data centers as a reason to accumulate shares while traders monitor critical support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Pessimistic Outlook for ABEO Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2026 EPS estimates for Abeona Therapeutics in a report released on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post ear...

Abeona Therapeutics (NASDAQ:ABEO) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday...

Abeona Therapeutics Q4 Earnings Call Highlights

Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric...

Abeona Therapeutics (NASDAQ:ABEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts' consensus...

Abeona Therapeutics Inc. $ABEO Shares Sold by Boone Capital Management LLC

Boone Capital Management LLC decreased its holdings in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 59.9% during the third quarter, according to its most recent disclosure with...

Q4 EPS Forecast for Abeona Therapeutics Increased by Analyst

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Stock analysts at HC Wainwright boosted their Q4 2025 EPS estimates for shares of Abeona Therapeutics in a research note issued on Tuesday...

Abeona Therapeutics Says ZEVASKYN Launch Is Back on Track, Eyes Profitability in 2026

Abeona Therapeutics (NASDAQ:ABEO) executives said the commercial launch of ZEVASKYN is gaining momentum after an early manufacturing-related delay, outlining progress on treatment center activation...

HC Wainwright Reaffirms "Buy" Rating for Abeona Therapeutics (NASDAQ:ABEO)

HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday...

Abeona Therapeutics (ABEO) Projected to Post Earnings on Tuesday

Abeona Therapeutics (NASDAQ:ABEO) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 17. (View Earnings Report at...

Abeona Therapeutics Inc. $ABEO Shares Sold by Western Standard LLC

Western Standard LLC lowered its holdings in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 40.2% during the third quarter, according to the company in its most recent filing with the SEC...

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

ABEO
Abeona Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ABEO News

ABEOAbeona Therapeutics Inc